查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1485047

伴侶動物藥品市場 - 全球產業規模、佔有率、趨勢、機會和預測，按適應症、動物、配銷通路、地區和競爭細分，2019-2029F

Companion Animal Pharmaceuticals Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Indication, By Animal, By Distribution Channel, By Region and Competition, 2019-2029F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2023 年全球伴侶動物藥品市場估值為145.2 億美元，預計在預測期內將穩定成長，到2029 年複合年成長率為8.25%。著成長。包括狗、貓和馬在內的伴侶動物在全世界數百萬人的生活中發揮著不可或缺的作用，導致針對其特定健康需求的藥物需求不斷成長。市場成長的關鍵驅動力之一是日益成長的寵物人性化趨勢，寵物被認為是家庭的重要成員。這種觀念的轉變使得寵物主人更願意投資於預防性醫療措施和治療，以確保毛茸茸的同伴的福祉。因此，對伴侶動物藥品的需求激增，從跳蚤和蜱蟲治療到治療關節炎和糖尿病等慢性疾病的藥物。獸醫學的進步和創新藥物配方的出現擴大了伴侶動物的治療選擇。獸醫現在可以獲得多種藥物和療法來解決寵物的各種健康問題，從常見疾病到複雜的醫療狀況。此外，新型藥物輸送系統（例如經皮貼片和調味藥物）的開發使寵物主人更容易給他們的動物服用藥物，從而提高依從性和治療效果。

市場概況
預測期 2025-2029
2023 年市場規模 145.2億美元
2029 年市場規模 232.7億美元
2024-2029 年複合年成長率 8.25%
成長最快的細分市場 皮膚科疾病
最大的市場 北美洲

伴侶動物疾病和病症的日益普及刺激了對藥物解決方案的需求。肥胖、過敏和牙齒問題等疾病在寵物中變得越來越普遍，這推動了對有效藥物和治療的需求。此外，由於獸醫護理和營養的改善，寵物的壽命更長，關節炎和認知功能障礙等與年齡相關的疾病的發病率不斷增加，進一步推動了對伴侶動物藥品的需求。從地理位置來看，北美在全球伴侶動物藥品市場中佔據主導地位，這歸因於較高的寵物擁有率、先進的獸醫保健基礎設施和強力的監管框架。由於寵物收養率提高、可支配收入增加以及人們對寵物健康和保健意識不斷增強，歐洲和亞太地區也佔有重要的市場佔有率。

儘管成長前景廣闊，但伴侶動物藥品市場仍面臨一定的挑戰。其中包括與藥物核准流程相關的監管障礙、定價壓力以及草藥補充劑和整體治療等替代療法的競爭。此外，持續的 COVID-19 大流行影響了市場動態，導致供應鏈中斷和消費者行為變化。

在獸醫學的持續進步、寵物人性化趨勢的發展以及全球寵物擁有率不斷上升的推動下，全球伴侶動物藥品市場的前景仍然樂觀。隨著寵物主人繼續優先考慮毛茸茸的伴侶的健康和福祉，對創新藥品和治療方法的需求預計將會上升。製藥公司、獸醫和研究機構之間的合作可能會推動市場的進一步創新和擴張，最終使全世界的伴侶動物及其主人受益。

主要市場促進因素

寵物擁有量不斷增加

增加可支配收入

主要市場挑戰

監管障礙

仿冒品

主要市場趨勢

技術進步

細分市場洞察

適應症見解

動物洞察

區域洞察

目錄

第 1 章：產品概述

第 2 章：研究方法

第 3 章：執行摘要

第 4 章：全球伴侶動物藥品市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依適應症（傳染病、皮膚病、疼痛、骨科疾病、行為疾病、其他）
    • 依動物分類（狗、貓、馬、其他）
    • 按配銷通路（獸醫院和診所、零售藥局、其他）
    • 按地區
    • 按公司分類 (2023)
  • 市場地圖
    • 按指示
    • 按動物分類
    • 按配銷通路
    • 按地區

第 5 章：亞太地區伴侶動物藥品市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按指示
    • 按動物分類
    • 按配銷通路
    • 按國家/地區
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 澳洲
    • 日本
    • 韓國

第 6 章：歐洲伴侶動物藥品市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按指示
    • 按動物分類
    • 按配銷通路
    • 按國家/地區
  • 歐洲：國家分析
    • 法國
    • 德國
    • 西班牙
    • 義大利
    • 英國

第 7 章：北美伴侶動物藥品市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按指示
    • 按動物分類
    • 按配銷通路
    • 按國家/地區
  • 北美：國家分析
    • 美國
    • 墨西哥
    • 加拿大

第 8 章：南美洲伴侶動物藥品市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按指示
    • 按動物分類
    • 按配銷通路
    • 按國家/地區
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第 9 章：中東和非洲伴侶動物藥品市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按指示
    • 按動物分類
    • 按配銷通路
    • 按國家/地區
  • MEA：國家分析
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 10 章：市場動態

  • 促進要素
  • 挑戰

第 11 章：市場趨勢與發展

  • 最近的發展
  • 產品發布
  • 併購

第 12 章：全球伴侶動物藥品市場：SWOT 分析

第 13 章：波特的五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 客戶的力量
  • 替代產品的威脅

第14章：競爭格局

  • Zoetis Services LLC
  • Merck & Co., Inc.
  • Boehringer Ingelheim International GmbH
  • Elanco Animal Health Incorporated
  • Virbac Taiwan Co., Ltd.
  • Vetoquinol SA
  • Dechra Pharmaceuticals Limited
  • Chanelle Pharma
  • KyoritsuSeiyaku Corp

第 15 章：策略建議

第16章調查會社について,免責事項

簡介目錄
Product Code: 22464

Global Companion Animal Pharmaceuticals Market was valued at USD 14.52 Billion in 2023 and is anticipated to project steady growth in the forecast period with a CAGR of 8.25% through 2029. The global companion animal pharmaceuticals market has witnessed significant growth in recent years, driven by a combination of factors including increasing pet ownership, rising awareness about pet health, and advancements in veterinary medicine. Companion animals, including dogs, cats, and horses, play an integral role in the lives of millions of people worldwide, leading to a growing demand for pharmaceutical products tailored to their specific health needs. One of the key drivers of market growth is the increasing pet humanization trend, where pets are considered valued members of the family. This shift in perception has led to a greater willingness among pet owners to invest in preventive healthcare measures and treatments to ensure the well-being of their furry companions. As a result, there has been a surge in the demand for companion animal pharmaceuticals, ranging from flea and tick treatments to medications for chronic conditions like arthritis and diabetes. Advancements in veterinary medicine and the availability of innovative pharmaceutical formulations have expanded the treatment options available for companion animals. Veterinarians now have access to a wide array of drugs and therapies to address various health issues in pets, ranging from common ailments to complex medical conditions. Additionally, the development of novel drug delivery systems, such as transdermal patches and flavored medications, has made it easier for pet owners to administer medications to their animals, improving compliance and treatment outcomes.

Market Overview
Forecast Period2025-2029
Market Size 2023USD 14.52 Billion
Market Size 2029USD 23.27 Billion
CAGR 2024-20298.25%
Fastest Growing SegmentDermatologic Diseases
Largest MarketNorth America

The increasing prevalence of diseases and disorders in companion animals has fueled the demand for pharmaceutical solutions. Conditions such as obesity, allergies, and dental problems are becoming more prevalent among pets, driving the need for effective medications and therapies. Additionally, as pets live longer due to improved veterinary care and nutrition, there is a growing incidence of age-related ailments such as arthritis and cognitive dysfunction, further driving the demand for companion animal pharmaceuticals. Geographically, North America dominates the global companion animal pharmaceuticals market, attributed to the high pet ownership rates, advanced veterinary healthcare infrastructure, and strong regulatory framework. Europe and Asia-Pacific also hold significant market shares, driven by increasing pet adoption rates, rising disposable incomes, and growing awareness about pet health and wellness.

Despite the promising growth prospects, the companion animal pharmaceuticals market faces certain challenges. These include regulatory hurdles associated with drug approval processes, pricing pressures, and competition from alternative therapies such as herbal supplements and holistic treatments. Additionally, the ongoing COVID-19 pandemic has impacted the market dynamics, leading to disruptions in supply chains and changes in consumer behavior.

The outlook for the global companion animal pharmaceuticals market remains positive, fueled by continued advancements in veterinary medicine, growing pet humanization trends, and increasing pet ownership rates globally. As pet owners continue to prioritize the health and well-being of their furry companions, the demand for innovative pharmaceutical products and treatments is expected to rise. Collaborations between pharmaceutical companies, veterinarians, and research institutions are likely to drive further innovation and expansion in the market, ultimately benefiting companion animals and their owners worldwide.

Key Market Drivers

Rising Pet Ownership

The global companion animal pharmaceuticals market has experienced significant growth, with a primary driving force being the increasing number of pets worldwide. As people's love and attachment to their furry and feathered friends continue to grow, the demand for products and medications designed to enhance the health and well-being of companion animals has surged. This trend not only benefits pets and their owners but also presents a wealth of opportunities for pharmaceutical companies and the broader veterinary industry. Pet ownership has become more popular than ever, with pets increasingly viewed as cherished members of the family. This shift in perspective has led to greater investments in the health and well-being of companion animals. As people's lifestyles become busier, many are turning to pets for companionship and emotional support, especially in urban areas where social connections may be limited. The increasing recognition of the positive impact pets can have on human mental health has driven more individuals to adopt pets, leading to an expansion of the pet market. Society's changing attitudes have led to a reduction in the stigma associated with renting or living in smaller spaces with pets, making pet ownership more feasible for a wider range of people. Rising income levels in many parts of the world have allowed individuals to allocate more resources to their pets, including pharmaceutical products and healthcare.

The flourishing pet ownership trend has led to a surge in demand for companion animal pharmaceuticals, creating a flourishing global market. These pharmaceuticals encompass a wide range of products, including medications, vaccines, supplements, and various healthcare products tailored for pets. Pet owners are increasingly proactive in safeguarding their pets' health. Regular veterinary check-ups, vaccinations, and preventive treatments are becoming the norm, leading to greater pharmaceutical sales. The growing elderly pet population means an increased need for medications to manage age-related conditions, such as arthritis, diabetes, and heart disease. This trend has created opportunities for pharmaceutical companies to develop and market specialized medications. The development of medications and treatments specifically formulated for companion animals has become a significant driver of the market. These tailored solutions cater to the unique needs and preferences of pet owners. Companion animal pharmaceutical companies are constantly innovating, offering an ever-expanding range of products, from oral medications and topical treatments to advanced surgeries and specialty diets. Pet owners are investing more in veterinary services, which often involve the prescription and administration of pharmaceuticals. This trend fosters a symbiotic relationship between the veterinary industry and the pharmaceutical sector.

Increasing Disposable Income

The global companion animal pharmaceuticals market is experiencing a significant surge in growth, and one of the primary factors fueling this expansion is the increasing disposable income of pet owners. In recent years, pets have become more than just loyal companions; they are now considered part of the family. This shift in perspective has led to a substantial increase in pet healthcare spending, driving the companion animal pharmaceuticals market to new heights. In today's world, pets are treated as family members, receiving the same love and care that humans do. This shift in attitude, often referred to as the humanization of pets, has led to an upsurge in spending on pet healthcare. Pet owners are more willing to invest in the health and well-being of their furry friends, leading to a boom in the global companion animal pharmaceuticals market.

The primary driver behind the companion animal pharmaceuticals market's growth is the rise in disposable income of pet owners. With higher disposable incomes, individuals are more inclined to provide their pets with better healthcare, nutrition, and overall well-being. This upward trend is observed not only in developed countries but also in emerging markets, where disposable income is steadily on the rise. With increasing disposable income, pet owners can afford advanced healthcare services and treatments for their animals. This includes regular veterinary check-ups, vaccinations, and preventive care. As a result, pharmaceutical companies have witnessed a surge in the demand for companion animal pharmaceuticals to cater to these growing healthcare needs. Pet owners are now opting for premium and specialized pharmaceutical products to address specific health issues their animals may face. This includes medications, supplements, and even therapeutic diets. The increasing disposable income allows pet owners to invest in these high-quality products to ensure their pets' health and happiness. Higher disposable income has also enabled pet owners to become more aware and educated about their animals' health needs. They are willing to invest in knowledge, ensuring that they make informed decisions about their pets' healthcare. As a result, the demand for pharmaceuticals and healthcare products has surged.

Key Market Challenges

Regulatory Hurdles

One of the significant challenges for the companion animal pharmaceuticals market is the complex and evolving regulatory landscape. The industry must navigate through a multitude of regulations and guidelines that vary from one country to another. Different regulatory bodies in different regions may require varying levels of testing, safety assessments, and approvals for pet medications and vaccines. This can make it difficult for companies to efficiently develop and market products on a global scale. As the demand for companion animal pharmaceuticals continues to grow, the market has become increasingly competitive. Numerous companies are entering the market, leading to a broader range of products and services. While this competition can be beneficial for consumers and the overall industry, it can pose challenges for established companies seeking to maintain market share and profitability.

Counterfeit Products

The global companion animal pharmaceuticals market is plagued by the issue of counterfeit products. Counterfeit medications and vaccines can be harmful to pets and undermine trust in the industry. Consumers need to be vigilant and purchase products from reputable sources. Manufacturers and regulatory authorities must work together to combat the production and distribution of counterfeit pharmaceuticals. While awareness of the importance of pet healthcare has increased, there is still room for improvement. Many pet owners may not fully understand the need for regular veterinary visits, vaccinations, and the use of pharmaceuticals. This lack of awareness can limit the market's growth potential, as pet owners may not seek preventive healthcare for their animals until health issues become severe.

Ethical concerns regarding the testing of pharmaceutical products on animals can be a significant challenge in the industry. Many consumers and animal welfare organizations demand more ethical and humane approaches to testing. Companies must invest in alternative testing methods and clearly communicate their commitment to animal welfare to maintain public trust. The global supply chain, like many industries, has faced disruptions in recent times, with events like the COVID-19 pandemic affecting the production and distribution of pharmaceuticals. Supply chain disruptions can lead to product shortages, delayed deliveries, and increased costs. Companies in the companion animal pharmaceuticals market must have resilient supply chain strategies in place to mitigate these challenges.

Key Market Trends

Technological Advancements

The global companion animal pharmaceuticals market has experienced significant growth over the years, and one of the key drivers behind this expansion is the continuous wave of technological advancements. As technology evolves, it enhances the research, development, and delivery of innovative pharmaceutical solutions for our beloved pets. Technological advancements in genomics and biotechnology have revolutionized the development of companion animal pharmaceuticals. Researchers can now better understand the genetic makeup of animals, allowing for the creation of personalized medicines tailored to an individual pet's needs. This level of precision ensures safer and more effective treatments.

The integration of telemedicine and telehealth platforms has allowed pet owners to access veterinary consultations and prescription medications more conveniently. With the help of remote monitoring, digital health records, and telepharmacy services, pet owners can receive expert advice and order medications online, reducing the need for physical visits to the vet. Advancements in drug delivery systems have made administering medications to pets easier and more effective. Innovative methods such as transdermal patches, oral syrups, and extended-release formulations improve pet owners' ability to ensure their animals receive the right dose of medication at the right time. The use of big data analytics and artificial intelligence has enabled pharmaceutical companies and veterinarians to analyze vast amounts of data to improve treatment outcomes. AI can help in diagnosing diseases, predicting treatment responses, and identifying potential side effects, leading to more precise treatment options.

Continuous technological advancements provide opportunities for pharmaceutical companies to develop novel therapies and medications for companion animals. This, in turn, allows veterinarians to provide a higher standard of care for their patients. With the rise of online platforms and e-commerce, pharmaceutical companies can reach a broader customer base. Pet owners can easily order medications and pet health products, increasing convenience and accessibility. As technology bridges global divides, pharmaceutical companies have the chance to expand their reach beyond domestic markets. The global companion animal pharmaceuticals market presents immense growth potential for companies willing to enter new regions. Technological advancements often require collaboration between pharmaceutical companies, veterinary practices, and technology providers. These partnerships can lead to the development of innovative solutions and improve the overall ecosystem of companion animal healthcare.

Segmental Insights

Indication Insights

Based on indication, dermatologic diseases emerged as the fastest growing segment in the global market for companion animal pharmaceuticals in 2023. Dermatologic diseases encompass a wide range of conditions that affect the skin, hair, and nails of companion animals. These conditions can be caused by a variety of factors, including allergies, infections, parasites, autoimmune disorders, and more. Dermatologic issues are common in both dogs and cats, and they often manifest as itching, rashes, hair loss, and skin infections. These ailments can significantly reduce the quality of life for pets and can be distressing for their owners.

The high prevalence of dermatologic diseases in companion animals has led to an increased demand for pharmaceutical products specifically designed to treat these conditions. This demand has a significant impact on the global companion animal pharmaceuticals market in several ways. To meet the needs of pet owners, pharmaceutical companies have been investing in research and development to create more effective and convenient treatments for dermatologic diseases. These innovations include new topical creams, shampoos, oral medications, and injections, allowing veterinarians and pet owners a broader array of options for managing these conditions. The rising incidence of dermatologic diseases has prompted pharmaceutical companies to expand their product lines. This means a greater variety of treatment options are now available, catering to different types of skin issues, severity levels, and pet preferences. Dermatologic conditions often require professional diagnosis and management. This has led to an increase in demand for veterinary services specializing in dermatology, further driving the need for pharmaceutical products. These specialists can provide tailored treatment plans and recommendations for companion animals with skin issues.

Animal Insights

Based on animal, dogs segment is projected to experience rapid growth in Global Companion Animal Pharmaceuticals Market during the forecast period. The global pet population is on the rise, with dogs being one of the most popular choices as companions. The emotional bond between humans and their dogs has driven pet owners to prioritize the health and well-being of their four-legged family members. As a result, there is a growing demand for pharmaceutical products and services tailored to dogs' unique healthcare needs. With advancements in veterinary medicine and nutrition, dogs are living longer, healthier lives. However, like humans, older dogs are prone to various health issues, such as arthritis, diabetes, and cardiovascular problems. This aging demographic of dogs has led to an increased need for specialized pharmaceuticals to address age-related ailments, ultimately contributing to the growth of the companion animal pharmaceuticals market.

The concept of preventive healthcare for pets has gained momentum in recent years. Dog owners are increasingly focused on keeping their pets healthy and preventing diseases rather than just treating them when they occur. This trend has led to the expansion of product lines that include vaccines, flea and tick preventatives, and nutritional supplements, all of which boost the companion animal pharmaceuticals market. As dogs continue to be considered integral members of the family, there has been a rise in the humanization of pets. Dog owners are more willing to invest in their pets' well-being, which includes spending on higher-quality foods, pharmaceuticals, and veterinary services. This shift in perspective has led to increased expenditures on companion animal pharmaceuticals.

Regional Insights

Based on region, North America emerged as the dominant region in the Global Companion Animal Pharmaceuticals Market in 2023, holding the largest market share in terms of value. One of the primary factors fueling the growth of the companion animal pharmaceuticals market in North America is the increasing trend of pet ownership. North America, particularly the United States and Canada, has seen a significant rise in the number of households that have pets, including dogs, cats, and other companion animals. These pets have become cherished members of the family, leading owners to invest in their well-being and healthcare. With more pets in homes, there is a higher demand for pharmaceutical products such as vaccines, medications, and supplements to maintain the health and longevity of these beloved animals. This surge in pet ownership is creating a robust market for pharmaceutical companies specializing in companion animal health.

North American pet owners are becoming increasingly aware of the importance of preventive healthcare for their animals. This awareness has translated into greater willingness to spend on veterinary care and pharmaceutical products. Regular check-ups, vaccinations, and treatments for common health issues have become the norm, further driving the demand for companion animal pharmaceuticals. Veterinarians in North America play a pivotal role in educating pet owners about the benefits of preventive care. They recommend and prescribe pharmaceutical products that cater to specific health needs, making them essential stakeholders in the companion animal pharmaceuticals market. As the awareness of pet healthcare continues to grow, the market for such products in North America is set to expand even further.

Key Market Players

Zoetis Services LLC

Merck & Co., Inc.

Boehringer Ingelheim International GmbH

Elanco Animal Health Incorporated

Virbac Taiwan Co., Ltd.

Vetoquinol S.A.

Dechra Pharmaceuticals Limited

Chanelle Pharma

KyoritsuSeiyaku Corp

Report Scope:

In this report, the Global Companion Animal Pharmaceuticals Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Companion Animal Pharmaceuticals Market, By Indication:

    Infectious diseases Dermatologic diseases Pain Orthopedic diseases Behavioural diseases Other

Companion Animal Pharmaceuticals Market, By Animal:

    Dogs Cats Horses Other

Companion Animal Pharmaceuticals Market, By Distribution Channel:

    Veterinary hospitals and clinics Retail pharmacies Others

Companion Animal Pharmaceuticals Market, By Region:

    North America

United States

Canada

Mexico

    Europe

France

United Kingdom

Italy

Germany

Spain

    Asia Pacific

China

India

Japan

Australia

South Korea

    South America

Brazil

Argentina

Colombia

    Middle East & Africa

South Africa

Saudi Arabia

UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Companion Animal Pharmaceuticals Market.

Available Customizations:

Global Companion Animal Pharmaceuticals Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Global Companion Animal Pharmaceuticals Market Outlook

  • 4.1. Market Size & Forecast
    • 4.1.1. By Value
  • 4.2. Market Share & Forecast
    • 4.2.1. By Indication (Infectious Diseases, Dermatologic Diseases, Pain, Orthopedic Diseases, Behavioral Diseases, Other)
    • 4.2.2. By Animal (Dogs, Cats, Horses, Other)
    • 4.2.3. By Distribution Channel (Veterinary Hospitals and Clinics, Retail Pharmacies, Others)
    • 4.2.4. By Region
    • 4.2.5. By Company (2023)
  • 4.3. Market Map
    • 4.3.1. By Indication
    • 4.3.2. By Animal
    • 4.3.3. By Distribution Channel
    • 4.3.4. By Region

5. Asia Pacific Companion Animal Pharmaceuticals Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Indication
    • 5.2.2. By Animal
    • 5.2.3. By Distribution Channel
    • 5.2.4. By Country
  • 5.3. Asia Pacific: Country Analysis
    • 5.3.1. China Companion Animal Pharmaceuticals Market Outlook
      • 5.3.1.1. Market Size & Forecast
        • 5.3.1.1.1. By Value
      • 5.3.1.2. Market Share & Forecast
        • 5.3.1.2.1. By Indication
        • 5.3.1.2.2. By Animal
        • 5.3.1.2.3. By Distribution Channel
    • 5.3.2. India Companion Animal Pharmaceuticals Market Outlook
      • 5.3.2.1. Market Size & Forecast
        • 5.3.2.1.1. By Value
      • 5.3.2.2. Market Share & Forecast
        • 5.3.2.2.1. By Indication
        • 5.3.2.2.2. By Animal
        • 5.3.2.2.3. By Distribution Channel
    • 5.3.3. Australia Companion Animal Pharmaceuticals Market Outlook
      • 5.3.3.1. Market Size & Forecast
        • 5.3.3.1.1. By Value
      • 5.3.3.2. Market Share & Forecast
        • 5.3.3.2.1. By Indication
        • 5.3.3.2.2. By Animal
        • 5.3.3.2.3. By Distribution Channel
    • 5.3.4. Japan Companion Animal Pharmaceuticals Market Outlook
      • 5.3.4.1. Market Size & Forecast
        • 5.3.4.1.1. By Value
      • 5.3.4.2. Market Share & Forecast
        • 5.3.4.2.1. By Indication
        • 5.3.4.2.2. By Animal
        • 5.3.4.2.3. By Distribution Channel
    • 5.3.5. South Korea Companion Animal Pharmaceuticals Market Outlook
      • 5.3.5.1. Market Size & Forecast
        • 5.3.5.1.1. By Value
      • 5.3.5.2. Market Share & Forecast
        • 5.3.5.2.1. By Indication
        • 5.3.5.2.2. By Animal
        • 5.3.5.2.3. By Distribution Channel

6. Europe Companion Animal Pharmaceuticals Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Indication
    • 6.2.2. By Animal
    • 6.2.3. By Distribution Channel
    • 6.2.4. By Country
  • 6.3. Europe: Country Analysis
    • 6.3.1. France Companion Animal Pharmaceuticals Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Indication
        • 6.3.1.2.2. By Animal
        • 6.3.1.2.3. By Distribution Channel
    • 6.3.2. Germany Companion Animal Pharmaceuticals Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Indication
        • 6.3.2.2.2. By Animal
        • 6.3.2.2.3. By Distribution Channel
    • 6.3.3. Spain Companion Animal Pharmaceuticals Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Indication
        • 6.3.3.2.2. By Animal
        • 6.3.3.2.3. By Distribution Channel
    • 6.3.4. Italy Companion Animal Pharmaceuticals Market Outlook
      • 6.3.4.1. Market Size & Forecast
        • 6.3.4.1.1. By Value
      • 6.3.4.2. Market Share & Forecast
        • 6.3.4.2.1. By Indication
        • 6.3.4.2.2. By Animal
        • 6.3.4.2.3. By Distribution Channel
    • 6.3.5. United Kingdom Companion Animal Pharmaceuticals Market Outlook
      • 6.3.5.1. Market Size & Forecast
        • 6.3.5.1.1. By Value
      • 6.3.5.2. Market Share & Forecast
        • 6.3.5.2.1. By Indication
        • 6.3.5.2.2. By Animal
        • 6.3.5.2.3. By Distribution Channel

7. North America Companion Animal Pharmaceuticals Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Indication
    • 7.2.2. By Animal
    • 7.2.3. By Distribution Channel
    • 7.2.4. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States Companion Animal Pharmaceuticals Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Indication
        • 7.3.1.2.2. By Animal
        • 7.3.1.2.3. By Distribution Channel
    • 7.3.2. Mexico Companion Animal Pharmaceuticals Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Indication
        • 7.3.2.2.2. By Animal
        • 7.3.2.2.3. By Distribution Channel
    • 7.3.3. Canada Companion Animal Pharmaceuticals Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Indication
        • 7.3.3.2.2. By Animal
        • 7.3.3.2.3. By Distribution Channel

8. South America Companion Animal Pharmaceuticals Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Indication
    • 8.2.2. By Animal
    • 8.2.3. By Distribution Channel
    • 8.2.4. By Country
  • 8.3. South America: Country Analysis
    • 8.3.1. Brazil Companion Animal Pharmaceuticals Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Indication
        • 8.3.1.2.2. By Animal
        • 8.3.1.2.3. By Distribution Channel
    • 8.3.2. Argentina Companion Animal Pharmaceuticals Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Indication
        • 8.3.2.2.2. By Animal
        • 8.3.2.2.3. By Distribution Channel
    • 8.3.3. Colombia Companion Animal Pharmaceuticals Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Indication
        • 8.3.3.2.2. By Animal
        • 8.3.3.2.3. By Distribution Channel

9. Middle East and Africa Companion Animal Pharmaceuticals Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Indication
    • 9.2.2. By Animal
    • 9.2.3. By Distribution Channel
    • 9.2.4. By Country
  • 9.3. MEA: Country Analysis
    • 9.3.1. South Africa Companion Animal Pharmaceuticals Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Indication
        • 9.3.1.2.2. By Animal
        • 9.3.1.2.3. By Distribution Channel
    • 9.3.2. Saudi Arabia Companion Animal Pharmaceuticals Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Indication
        • 9.3.2.2.2. By Animal
        • 9.3.2.2.3. By Distribution Channel
    • 9.3.3. UAE Companion Animal Pharmaceuticals Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Indication
        • 9.3.3.2.2. By Animal
        • 9.3.3.2.3. By Distribution Channel

10. Market Dynamics

  • 10.1. Drivers
  • 10.2. Challenges

11. Market Trends & Developments

  • 11.1. Recent Developments
  • 11.2. Product Launches
  • 11.3. Mergers & Acquisitions

12. Global Companion Animal Pharmaceuticals Market: SWOT Analysis

13. Porter's Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Product

14. Competitive Landscape

  • 14.1. Zoetis Services LLC
    • 14.1.1. Business Overview
    • 14.1.2. Company Snapshot
    • 14.1.3. Product & Services
    • 14.1.4. Financials (In case of listed)
    • 14.1.5. Recent Developments
    • 14.1.6. SWOT Analysis
  • 14.2. Merck & Co., Inc.
  • 14.3. Boehringer Ingelheim International GmbH
  • 14.4. Elanco Animal Health Incorporated
  • 14.5. Virbac Taiwan Co., Ltd.
  • 14.6. Vetoquinol S.A.
  • 14.7. Dechra Pharmaceuticals Limited
  • 14.8. Chanelle Pharma
  • 14.9. KyoritsuSeiyaku Corp

15. Strategic Recommendations

16. About Us & Disclaimer